BJ047

BJ047 is an investigational recombinant protein therapy being developed by Shanghai Bao Pharmaceuticals (Bao Pharma) for the treatment of IgG-mediated autoimmune diseases. Currently in the preclinical stage of development, BJ047 is part of the company's portfolio that leverages modern recombinant manufacturing technologies to create alternatives to traditional plasma-derived treatments. While the specific molecular target and mechanism of action have not been publicly disclosed, the drug is designed to address conditions characterized by the presence of pathogenic immunoglobulin G (IgG) antibodies. It is developed alongside other candidates in the same therapeutic category, such as KJ103 (Ricefidase), a recombinant IgG-degrading enzyme.